New interview with Eric Topol, MD, on the state of artificial intelligence in precision oncology

An interview with Eric J. Topol, MD, a world-renowned cardiologist, best-selling author of several books on personalized medicine, and the founder and director of the Scripps Research Translational Institute in La Jolla, California, has been published. in the new peer-reviewed journal, AI in Precision Oncology. Dr. Topol is an advocate for using digital technologies and artificial intelligence in health care. click here to read the interview now.

Douglas Flora, MD, Editor-in-Chief of AI in Precision Oncology, interviewed Dr. Topol during the opening keynote session of the journal’s inaugural virtual summit, “The State of AI in Precision Oncology.”

“Over the next couple of years, I’m hoping we’ll start to see cancer screening get upended,” said Dr. Topol. We won’t have it finalized, but at least some of the trials are ongoing to challenge the old way of doing cancer screening. We will get a diagnosis improved, whether it’s because the accuracy of scan interpretation in the next couple of years or whether it’s because each doctor through their health system practice has access to a GPT support that gives them a differential diagnosis of difficult diagnoses.”

About the Journal
AI in Precision Oncology is the only peer-reviewed journal dedicated to the advancement of artificial intelligence applications in clinical and precision oncology. Spearheaded by Editor-in-Chief Douglas Flora, MD and supported by a diverse and accomplished team of international experts, the Journal provides a high-profile forum for cutting-edge research and frontmatter highlighting important research and industry-related advances rapidly developing within the field. For complete information, visit the AI in Precision Oncology website.

About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc. website.